Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial

Tracey A. Day, Adam Penn‐Nicholson, Angelique Kany Kany Luabeya, Andrew Fioré-Gartland, Nelita du Plessis, André G. Loxton, Julie Vergara, Tom Rolf, Tim Reid, Asma Toefy, Justin Shenje, Hendrik Geldenhuys, Michèle Tameris, Simbarashe Mabwe, Nicole Bilek, Linda‐Gail Bekker, Andreas H. Diacon, Gerhard Walzl, Jill A. Ashman, Aude Frevol, Zachary K. Sagawa, Cecilia S. Lindestam Arlehamn, Alessandro Sette, Steven G. Reed, Rhea N. Coler, Thomas J. Scriba, Mark Hatherill, Anna Marie Beckmann, Fan‐Chi Hsu, Sarah Albertson, Ashley Veldsman, Constance Schreuder, Erica Smit, Yolundi Cloete, Cynthia Ontong, Elisabeth Filander, Gail Jacobs, Alana Keyser, Hadn Africa, Humphrey Mulenga, Julia Noble, Lebohang Makhethe, Marcia Steyn, Marwou de Kock, Nambitha Quaqua, Yiwen Lu, Andrea Gutschmidt, Friedrich Thienemann, Stuart J. Kahn, Angelique Mouton, Elma van Rooyen, Fajwa Opperman, Ann Swarts, Amaryl Van Schalkwyk, Yolandi Herselman, Devona Hofmeester, Julia Amsterdam, Leya Hassanally, Linda van der Merwe, Alessandro Companie, Susan Rossouw, Carolyn Jones, Natasja Botes, Elize van der Riet, Sandra Goliath, Sandra Krüger, Eunice Sinandile